home / stock / immp / immp news

IMMP News and Press, Immutep Limited From 12/06/22

Stock Information
Company Name: Immutep Limited
Stock Symbol: IMMP
Market: NASDAQ
Website: immutep.com
Menu
IMMP IMMP Quote IMMP Short IMMP News IMMP Articles IMMP Message Board
Get IMMP Alerts

News, Short Squeeze, Breakout and More Instantly...
IMMP - Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Media Release SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced t...
IMMP - Immutep to Participate in The JMP Securities Hematology and Oncology Summit

Media Release SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today annou...

IMMP - Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combination of eftilagimod alpha (“efti”) and avelumab (BAVENCIO®) Expansion into urothelial cancer builds on core strategy to in...

IMMP - Immutep Receives Australian R&D Tax Incentive

Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$986,286 (~US$659,303) cash reb...
IMMP - Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Media Release O verall response rate (ORR) increase s to 40.4% , according to iRECIS T, in TACTI-002 all-comer PD-L1 Phase II trial in 1st line non-small cell lung cancer ( 1L NSCLC) ORR improved across all ...

IMMP - Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022

Media Release First activity evaluat ion of efti as part of triple combination therapy yields p romising early results with 72.7% response rate and 90.9 % disease control rate in 1 st l ine N...

IMMP - Immutep gets patents in Japan, South Korea linked to immunotherapy eftilagimod

Immutep ( NASDAQ: IMMP ) said it was granted two patents (numbers 7160345 and 10-2441425) by the Japanese Patent Office and South Korean Patent Office, respectively. The patents titled 'Combined Preparations for the Treatment of Cancer' protects intellec...
IMMP - Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

Media Release SYDNEY, AUSTRALIA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is...

IMMP - Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference

Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference Company to h ost Webcast on Thursday, 10 th November at 5 PM ET to d ...

IMMP - Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Media Release SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, tod...
Previous 10 Next 10